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The natural history of Fanconi anemia remains hard to establishbecause of its rarity and its heterogeneous clinical presentation; since1994, the Italian Fanconi Anemia Registry has collected clinical, epi-
demiological and genetic data of Italian Fanconi Anemia patients. This reg-
istry includes 180 patients with a confirmed diagnosis of Fanconi anemia
who have either been enrolled prospectively, at diagnosis, or later on. After
enrollment, follow-up data were periodically collected to assess the clinical
course, possible complications and long-term survival; the median follow up
was 15.6 years. The main goal of the study was to describe the natural his-
tory of Fanconi anemia, focusing on the following variables: family history,
disease presentation, development of hematological manifestations, devel-
opment of malignancies, occurrence of hematopoietic stem cell transplanta-
tion and survival. Typical morphological and/or hematological abnormalities
and/or growth retardation were the most common manifestations at diagno-
sis; the majority of patients (77%) exhibited hematological abnormalities at
the initial presentation, and almost all (96%) eventually developed hemato-
logical manifestations. More than half of the patients (57%) underwent a
bone-marrow transplant. The occurrence of cancer was quite rare at diagno-
sis, whereas the cumulative incidence of malignancies at 10, 20 and 30 years
was 5%, 8% and 22%, respectively, for hematological cancers and 1%, 15%
and 32%, respectively, for solid tumors. Overall survival at 10, 20 and 30
years were 88%, 56% and 37%, respectively; the main causes of death were
cancer, complications of the hematological presentation and complications of
transplantation. These data clearly confirm the detrimental outcome of
Fanconi anemia, with no major improvement in the past decades.
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ABSTRACT
Introduction
Fanconi anemia (FA)1 is a rare inherited hematological disorder biologically char-
acterized by hypersensitivity to DNA cross-linking agents. FA is mainly an autoso-
mal recessive disease (except the rare X-linked FANC-B form), which was first
reported in 1927 by the Swiss pediatrician Guido Fanconi as familial, infantile ane-
mia.2 FA is now defined as a chromosomal instability (CI) syndrome, and it shows
a wide clinical and genetic heterogeneity. Indeed, genetically FA can be caused by
mutations in at least 18 different genes, mostly cooperating in a pathway which has
not yet been fully elucidated. These gene products somehow interact with proteins
encoded by genes which, when mutated, cause other CI syndromes, such as Ataxia
Teleangiectasia, Bloom syndrome, and Nijmegen Breakage Syndrome.3 All these
proteins cooperate in a pathway  which appears to be involved in DNA and oxida-
tive stress damage repair.4 The FA cellular phenotype is characterized by a G2 cell
cycle phase delay5 and by CI, typically appearing as characteristic rearrangement
figures (triradial and quadriradial figures made by non-
homologous chromosomes). The CI is both spontaneous6
and/or induced by alkylating DNA cross-linking agents,
such as mytomicin C (MMC)7 or the more specific
diepoxybutane (DEB);8 the cytogenetic DEB-test makes
the FA diagnosis possible in those patients not showing
typical malformations or still asymptomatic, and also in
patients not showing spontaneous CI at standard cytoge-
netic evaluation.
The phenotype of FA patients is largely heterogeneous,
since the natural history of the disease entails different
clinical manifestations which may either be present at
birth, or develop later during the course of the disease.
Clinically, FA patients present bone marrow failure at var-
ious times in life, typically beginning in childhood as
platelet deficiency, and then progressing to pancytopenia,1
eventually leading to life-threatening complications. FA
patients can show variable congenital malformations9 and
are prone to hematologic and solid neoplasias, which are
ultimately the leading cause of death.1,4,10-12 At present,
hematopoietic stem cell transplantation (HSCT) repre-
sents the only effective treatment for FA,13 although unfor-
tunately it cannot improve the patient’s growth rate or
reduce the propensity to develop non-hematological can-
cers.
FA is a rare disease, with an incidence rate of 0.1-0.5
new cases for every 100000 newborn children;1,14 thus,
large multicenter studies are needed to better describe the
natural history of the disease. Ideally, to prevent any bias,
such studies should include all patients diagnosed with FA
in a broad but well-defined geographic area, possibly with
a prospective collection of data and an adequate long-term
follow-up. Until now, the most reliable data on FA has
come from the International Fanconi Anemia Registry
(IFAR)15,16 and some national Registries, mostly the North
American Survey of Fanconi Anemia (NAS)12,17 and the
German Fanconi Anemia Registry (GEFA).18 In a rare and
highly heterogeneous disease such as FA, it is very difficult
to establish the natural history of the disease, and even
more difficult to organize research projects which require
the collection of samples from patients showing common
features. Moreover, some significant differences are possi-
ble among different populations, due to the existence of
geographic isolates or genetic derives. A specific national
registry, collecting patients’ clinical, epidemiological,
genetic and familial data, becomes a powerful tool, which
creates for physicians and the scientific community the
possibility of better knowing the disease, hence prevent-
ing misdiagnosis and delayed diagnosis.  A national reg-
istry also creates a network that facilitates the participa-
tion of patients in research projects and clinical trials.
To fulfill the need for a National Database including
most (if not all) FA patients diagnosed in Italy, in 1994 some
of us started “Il Registro Italiano Anemia di Fanconi” (RIAF),
which translates as 'The Italian Fanconi Anemia Registry'.19
This project was established within the Italian Public
National Health System (NHS), at the Genetic Unit of the
local health unit “ASL Napoli 1”, taking advantage of their
established expertise in diagnostics and genetic counseling
for CI syndromes. The aims of the project were: i. to create
a National database, recording all Italian FA cases; ii. to col-
lect information about the epidemiology of FA in Italy, as
well as about its natural history and therapeutic interven-
tions; iii. to promote a robust scientific network among
health workers (physicians, but also scientists) dealing
with FA in Italy, eventually increasing awareness about the
disease and promoting the strongest possible collaboration
among Italian physicians and scientists; iv. to provide
patients and their families with an established national net-
work for the diagnosis, treatment and follow-up of FA
patients; v. to share with the Italian authorities all the infor-
mation above, aiming to assess the real impact of FA on the
Italian NHS, eventually promoting further health policy
strategies. Herein we report on the 20-year experience of
this Registry, focusing on the natural history of the disease,
frequent therapeutic modalities and long-term outcomes of
FA patients. The major aim of this work was to identify
possible factors affecting the survival of FA patients, as well
as to identify possible changes in outcome emerging over
the two decades of this study.
Methods
Study design and data handling
The RIAF was officially established in 1994 as a prospective,
non-interventional study, approved by the local Government
(serving as the institutional review board, IRB) and operated
according to National laws within the NHS. The program was
approved and funded by the Regional Government (Regione
Campania), and supported by the Italian Association for Research
on Fanconi Anemia (AIRFA). All patient data were collected
through dedicated case report forms (CRFs), designed by the
geneticists working at the ASL Napoli 1, and further developed
thanks to the contributions of collaborating physicians (listed in
the Appendix). In accordance with the Declaration of Helsinki,
before enrollment all patients or their parents/guardians gave writ-
ten, informed consent, after discussing the RIAF aims and policy
and their own rights with an authorized delegate (geneticist or
physician), as listed in a written information sheet. Follow-up
CRFs were periodically filed by the geneticists or the physicians,
through a continuous sharing of critical information with both
treating physicians and patients or their families. The CRFs and
informed consent were approved by the local Government/IRB.
The data were stored both on paper and in digital records, strictly
protected, accessible only to the authorized staff and always made
anonymous for publications or sharing with other researchers.
Inclusion criteria, enrollment and data collection
Patients were enrolled only after a positive DEB or MMC test,
for the most part carried out or confirmed in our laboratory. The
chromosome breakage assay was always performed on peripheral
blood cells. Patients were enrolled either at the time of initial diag-
nosis, or later, during the course of the disease, according to
patients’ and/or parents’ decisions. Following informed consent,
family history and medical information were recorded by the
treating physicians, according to the specific CRFs. Given the epi-
demiologic purpose of the RIAF, the data of patients belonging to
non-Italian ethnic populations were collected separately and are
not considered here. Indeed, the patients geographic designation
was established on the basis of their parents’ and grandparents’
birthplaces (Caucasian ethnicity and proven Italian descent cover-
ing at least two generations); the same criteria were used to assign
a patient to a specific Italian Region. 
Data analysis and statistics
Statistical analysis was performed on the population of 180
patients (fetal losses and miscarriages were excluded), focusing on
the following categories: family history, disease presentation,
hematologic manifestations, HSCT, treatment impact on survival,
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malignancies, overall and cancer-free survival, and causes of death.
Standard descriptive statistical tests were applied as appropriate,
using SPSS software (PSP, Bologna, Italy). Student’s t-test, Mann-
Whitney test and Fisher’s exact test were used for most descriptive
analysis. The time to developing specific disease presentation (i.e.,
hematological presentation, hematological malignancies, solid
tumors) was presented as cumulative incidence, using a competing
risk approach, with birth treated as the FA onset date; death and
HSCT (the latter only for hematological presentation and hemato-
logical malignancies) were considered as competing risks. The
Kaplan-Meier curve was used to estimate overall survival; again
birth was considered as the FA onset date. The following variables
were tested for a possible impact on survival: gender, date of birth,
age at diagnosis, all congenital abnormalities (presence, total num-
ber, type; with and without skin abnormalities), hematological
presentation (at diagnosis, or at any time), hematological malig-
nancies, solid tumors (all together and head/neck) and HSCT.
Univariate and multivariate analyses were performed using a Cox
regression model on all patients, as well as separately on trans-
planted and non-transplanted patients.
Results
Diagnosis and genetics of FA
A preliminary diagnosis of FA was made by treating
physicians, based on clinical presentation at birth, or later
on; in some patients their family history was the main rea-
son to hypothesize the presence of FA. The diagnosis of
FA was based on a standard chromosome breakage test by
exposure to DEB or MMC, performed on peripheral blood
samples. Given the possible challenges in the diagnosis of
CI, all tests were confirmed at the Genetic Unit of the ASL
Napoli 1, or other laboratories with specific expertise for
the diagnosis of FA, eventually limiting subjective inter-
pretations and inter-laboratory technical variability.
Lymphoblastoid cell lines were established for research
aims and as diagnostic positive controls. A single DEB test
was sufficient for the diagnosis in the majority of cases;
however, the protocol adopted at the Genetic Unit of the
ASL Napoli 1 was used to confirm the diagnosis on two
different samples, allowing a robust consistency of data.
Between 1989 and 2014, out of a total of 1340 DEB tests
performed on 1185 subjects, the number of positive tests
was 206 (for 135 patients). Notably, a prior misdiagnosis
was proven in 11 patients: in 7 cases a previous diagnosis
of FA was not confirmed, whereas in 4 patients the diag-
nosis of FA was missing. Mosaicism was suspected in 9%
of patients.20 They showed chromosome breaks in <40%
of their cells, but typical DEB-induced rearrangements
were demonstrated; CI testing performed on different tis-
sues, together with clinical, family and/or molecular data,
confirmed the FA diagnosis. Patients lacking a confirmato-
ry positive chromosome breakage test were not enrolled
in the RIAF, irrespective of their clinical presentation; thus,
possible revertant phenotypes may be underrepresented
in this cohort. Complementation groups were available
for 55 patients; the most common complementation
group was A (91%), followed by G (5%) and D2 (4%)
(Online Supplementary Table S1).
Subject characteristics
Between 1994 and 2014, a total of 180 patients were
included in the RIAF, belonging to 151 distinct families
(median number of affected subjects per family was 1,
range 1-4; Table 1); a few (n=3) cases of miscarriage diag-
nosed as FA (by DEB and/or molecular tests on amnio-
cytes or chorionic villi) were also recorded, but were not
included in this study. The geographical distribution was
spread throughout the country, even if a significant num-
ber of patients were from the North-East or the South of
Italy;21 however, we were unable to identify any founder
effect. The characteristics of enrolled patients are
described in Table 2. There were 94 (52%) male and 86
(48%) female patients, with no statistical difference in
gender. The median age at diagnosis was 7.48 years; when
patients were divided according to the date of birth, by
quartiles (≤1980, 1981-1987, 1988-1995, ≥1996), the age at
diagnosis was significantly lower in patients born in more
recent periods (Mann-Whitney test, P<0.001; Figure 1A).
Family history
Family history was carefully collected for all patients
included in the registry; parents consanguinity was record-
ed in 20 of the 151 families (14%; Table 1). For each family
(considered as two parents), the median number of affect-
ed children was 1 (range 1-4), the median of unaffected
siblings (all confirmed by DEB test: all alive siblings were
tested even as potential HSCT donors) was 1 (range 0-10);
the median of miscarriages was 0 (range 0-3). Globally, in
the 151 families enrolled we recorded 310 babies, of
whom 183 (60%) were FA cases (180 enrolled in the RIAF
and 3 miscarriages), and 127 were unaffected siblings.
Thirty-seven of the patients included in the registry
reported a family history of FA. We also looked for the
occurrence of hematological disorders and malignancies in
the relatives of enrolled FA patients (up to the second
degree of kinship); family history for cancer (taking into
account up to the second degree) was 56% (85 out of 151).
Family history for hematological disorders was demon-
strated in 19% of patients. Morphological abnormalities in
some relatives were recorded in 19% of patients.
Disease presentation
In the majority of patients the diagnosis was suspected
based on typical morphological and/or hematological
abnormalities and/or growth retardation. As detailed in
The Italian Fanconi Anemia Registry
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Table 1. Characteristics of the 151 families.*
Variable                                                                       151 Families (%)
Consanguinity between parents            None                               131 (86)
                                                                       1st degree                         13 (9)
                                                                       2nd degree                         3 (2)
                                                                      >2nd degree                      4 (3)
N. of affected children°                          1                                       124 (82)
                                                                       2                                        22 (14)
                                                                       3                                          4 (3)
                                                                      4                                          1 (1)
N. of not affected children                     0                                        35 (23)
                                                                       1                                        65 (43)
                                                                       2                                        36 (24)
                                                                      3 or >3                            15 (10)
N. of miscarriages                                     0                                                                122 (81)
                                                                       1                                        21 (14)
                                                                                                                       2                                          7 (5)
                                                                      3 or >3                             1 (<1)
*For this analysis, a family is intended as two parents with their children; data are
expressed by family; °including abortions with confirmed FA.
Table 2, congenital abnormalities were demonstrated in
90% of patients at the time of diagnosis; the most com-
mon were the typical abnormalities of skin pigmentation,
which affected 96% of RIAF patients (Table 2); skeletal
abnormalities were also very frequent (57%). Other com-
mon congenital abnormalities involved growth retarda-
tion (39%), the central nervous system (35%), the urinary
system (34%), the genital tract (18%), the gastrointestinal
tract (13%), the eyes (12%), the endocrine system (9%) or
the cardiovascular system (7%). Hematological manifesta-
tions were defined according to the definition of aplastic
anemia22 and in accordance with the WHO 2008 classifica-
tion of myeloid malignancies.23 The majority of patients
(77%) exhibited some hematological abnormalities at
diagnosis, which in most cases was a mild-to-moderate
cytopenia eventually associated with some degree of bone
marrow failure (BMF), whereas hematological malignan-
cies (e.g., myelodysplastic syndromes, MDS) and solid
tumors were very rarely observed at diagnosis (Table 2).
Thanks to the long-term follow-up of the enrolled
patients, we were able to assess the further course of the
disease with the development of the most common com-
plications of FA, as well as the impact of different factors
on survival.
Time to hematological manifestations: bone marrow
failure and hematological malignancies
Even if hematological abnormalities were present at
diagnosis in only 77% of cases, a total of 172 (96%) of FA
patients enrolled in the RIAF had some hematological
manifestations during their disease course; in almost all
cases (172, 96%) this included cytopenia due to BMF,
whereas a hematological malignancy (mostly MDS or
acute leukemia, n=9 and n=4, respectively) was recorded
in 8% of patients (see Table 3). As expected, in many
cases an initial BMF progressed to either MDS or more
aggressive hematological cancers; 1 MDS, 1 leukemia and
1 lymphoma patient did not evolve from a previous BMF.
Considering death and HSCT as competing events, the
cumulative incidence of any hematological disorder was
62%, 88% and 94% at 10, 20 and 30 years respectively,
whereas the incidence of hematological malignancies was
5%, 8% and 22% at 10, 20 and 30 years, respectively.
'The cumulative incidence of the first hematological pres-
entation and of the first hematological malignancy is
depicted in Figure 1B.
Time to hematopoietic stem cell transplantation
The development of a hematological presentation is the
main indication for HSCT in FA patients; indeed, more
than half of the patients enrolled in the RIAF (102 out of
180, 57%) had received a HSCT from either a non-affect-
ed sibling or matched unrelated donor (Table 3). The first
HSCT was performed from a non-affected sibling in 38%
of cases, from a matched unrelated donor in 48%, and
quite rarely from cord blood (4%) or a mismatched related
donor (0.9%). The cumulative incidence of HSCT in our
patient cohort was 33%, 64% and 72% at 10, 20 and 30
years, respectively, as depicted in Figure 1B. The age at
transplant was significantly different according to the date
of birth cohorts, since patients born in more recent years
were transplanted earlier (Mann-Whitney test, P<0.001;
Figure 1C). Since National and European Registries collect-
ing transplant-specific information exist,15,16 in the RIAF we
decided not to duplicate this information. A formal analy-
sis of HSCT outcome in these patients is beyond the scope
of this study. However, follow-up data on survival and the
possible development of malignancies were also collected
for those RIAF patients who received a HSCT.
Cumulative incidence of solid tumors
A total of 27 solid cancers were diagnosed in 20 of the
180 RIAF patients (11%); a few patients experienced mul-
tiple cancers. The most common sites of cancer were the
head and neck (n=12, 44% of all solid tumors), liver (n=3,
11%), breast, thyroid and genital tract (n=2 for each, 7%)
(see Table 3 for details). The cumulative incidence of solid
tumors was 1%, 15% and 32% at 10, 20 and 30 years
respectively, as depicted in Figure 1B. The incidence of all
solid cancers and of head and neck tumors was not statis-
tically different between patients who had received a
HSCT and those who had not (P=0.43 and P=0.50, respec-
A.M. Risitano et al.
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Table 2. Patient characteristics at diagnosis.
Variable                                                                         180 Patients (%)
Gender                                                                                                             
Female                                                                                                   86 (48)
Male                                                                                                       94 (52)
Age (median years at diagnosis)                                                  7,48 (0-37,7)
Family history
no                                                                                                           143 (79)
yes                                                                                                           37 (21)
Family history for malformations
no                                                                                                           145 (81)
yes                                                                                                           35 (19)
Family history for hematological diseases
no                                                                                                           145 (81)
yes                                                                                                           35 (19)
Family history for cancer
no                                                                                                            79 (44)
yes                                                                                                          101 (56)
Congenital abnormalities                                                                          
none/unknown                                                                                     17 (10)
skin only                                                                                                 16 (9)
structural abnormalities*                                                               147 (81)
Type of malformation                                                                                   
skin hyper- hypopigmentation                                                        163 (96)
skeletal abnormalities                                                                      103 (57)
growth retardation                                                                              70 (39)
central nervous system                                                                       63 (35)
renal and urinary tract                                                                       61 (34)
genital tract                                                                                          33 (18)
gastrointestinal tract                                                                          23 (13)
eyes                                                                                                         21 (12)
endocrine system                                                                                  16 (9)
cardiovascular system                                                                         12 (7)
Hematological disease                                                                               
BMF*
no                                                                                                            42 (23)
yes                                                                                                          138 (77)
Hematological malignancies^
no                                                                                                           179 (99)
yes                                                                                                             1 (1)
Solid tumors
no                                                                                                           177 (98)
yes                                                                                                             3 (2)
*As defined according to the International Agranulocytosis and Aplastic Anemia Study
Group; ^As defined according to the WHO 2008 criteria.
tively; Figure 1D), even if the analysis is limited by the
small number of events. In transplanted patients, all but
one tumor occurred after HSCT.
Overall survival and prognostic factors
Ninety-four of the 180 patients were still alive at the time
of the last follow-up. For all patients enrolled in the RIAF,
overall survival was calculated starting from the day of
birth. With a median follow up of 15.6 years, median sur-
vival was 22.5 years (Figure 2A); probabilities of survival at
10, 20 and 30 years were 88%, 56% and 37%, respectively
(without censoring HSCT patients). Looking for the natural
history of the disease, when patients who had received an
allogeneic HSCT were censored at the time of transplant,
the probabilities of survival at 10, 20 and 30 years were
85%, 39% and 24%, respectively (Figure 2B). In univariate
analysis, no patients feature affected overall survival, except
age at diagnosis and the number of structural abnormalities
(excluding skin anomalies; Online Supplementary Table S2).
In multivariate analysis, an older age at diagnosis
(HR=0.873, P<0.001) and the presence of more than 10
structural abnormalities (excluding skin; HR=6.504,
P=0.017) were associated with a better or worse survival
rate, respectively. This distinction resulted in statistically
significant differences in overall survival based on age at
diagnosis (Figure 2C; P<0.001) and on higher numbers of
structural abnormalities (Figure 2D; P<0.005). Notably, BMF
at initial presentation, date of birth cohorts and HSCT
seemed not to affect survival (Table 4). Indeed, looking at
overall survival by quartiles of date of birth there was no
improvement in survival over time (Figure 2E; P=n.s.).
Similarly, grouping patients by HSCT, the 10, 20 and 30
year survival rate of non-transplanted patients (n=78, medi-
an follow-up 15.8 years) were 84%, 49% and 34%, respec-
tively, while those of transplanted patients (n=102, median
follow-up 16 years) were 90%, 62% and 40%, respectively
(Figure 2F; P=0.17). Multivariate analysis was also per-
formed separately on non-HSCT and HSCT patients; in this
context, age at diagnosis remained associated with a better
survival rate in both groups (Online Supplementary Table S3).
Cause of death
Eighty-six of the 180 FA patients enrolled in the RIAF
died during their follow-up; the main causes of death are
listed in Table 5. As expected, the causes of death were
different in patients who had not received an HSCT as
compared with those of transplanted patients (P<0.001;
Chi-square test). Indeed, in non-HSCT patients the main
causes of death were related to the underlying disease (i.e.,
for the most part the hematological abnormalities), such as
The Italian Fanconi Anemia Registry
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1. Time to most common FA complications. (A) Age at diagnosis, according to quartiles of date of birth (DOB); (B) Cumulative incidence of bone marrow failure (BMF),
hematological malignancies (MDS and AML; HEM TUM), solid tumors (SOL TUM) and HSCT; (C) Age at HSCT, according to DOB quartiles; (D) Cumulative incidence of
solid tumor and of head/neck tumors: HSCT vs. no HSCT.
A B
C D
infections (n=14, 33% of total deaths in non-HSCT
patients), bleeding (n=8, 18.5%) and solid tumors (n=9,
21%). In contrast, in HSCT patients the majority of deaths
were somehow related to treatment complications, such
as infections (n=11, 25.5% of total deaths in HSCT
patients), graft versus host disease (GvHD) (n=11, 25.5%)
and other transplant related mortality (TRM) (n=13, 30%).
Solid tumors accounted for 9% of deaths (n=4). 
Discussion
The RIAF is the first population-based Italian database,
run within the Italian NHS, focusing on FA, which is rare
in the frequency of the disease, but the most common
among inherited bone marrow failure syndromes. Herein
we report a comprehensive analysis of all patients includ-
ed in the registry over the past 20 years with their long-
term follow-up, eventually providing a reliable description
of the natural history of FA. In our series of 180 prospec-
tively collected patient data, we have shown a median sur-
vival of 22 years, which unfortunately has not improved in
the past two decades. Our efforts of creating a robust sci-
entific network have increased the awareness of this dis-
ease in Italy, eventually leading to objective achievements.
Indeed, the diagnosis has come to be made earlier over the
past decades, and the time to the only curative treatment
– namely HSCT – has decreased. Nevertheless, these
improvements in the management of FA patients have not
yet resulted in a better survival rate, and even the outcome
of patients who have received a HSCT does not appear to
be better than that of those who did not. Indeed, in our
multivariate analysis, the only factors associated with a
better outcome were an older age at diagnosis and a lower
number of structural abnormalities, indicating that differ-
ent clinical phenotypes may have a different life expectan-
cy.
The natural history of FA has been described in previous
retrospective studies,15-18 which have highlighted the het-
erogeneity of clinical presentation. The RIAF includes only
patients with a DEB test confirmed diagnosis of FA, who
are unselected for specific disease presentations and have
a long-term follow-up. Thus, selection biases (e.g., toward
a severe phenotype) should be limited (with the only
exception being a possible underestimation of patients
beginning with cancers, who might not receive the correct
FA diagnosis), eventually leading to a more accurate repre-
sentation of the natural history of FA. However, like all
registry studies, the RIAF suffers from potential limita-
tions, since its completeness and accuracy largely depends
on the commitment and dedication of collaborating physi-
cians. Our database confirms that FA severely impairs the
survival of affected patients; the median survival observed
in our series (about 22 years) was slightly lower than those
reported by the International Fanconi Anemia Registry16
and by the USA National Cancer Institute.24 In our
Registry, we have not systematically investigated any
genotype-phenotype correlation;25 however, genetic data
from a subset of patients (as well as independent data on
the genetics of FA in the same geographic area)26 seem pre-
dominantly influenced by the large prevalence of patients
harboring FANCA mutations.21,27 Malignancies play an
important role in the natural history of FA, the risk increas-
ing with age for a wide array of cancer types;10-12,18 more-
over, some patients can develop multiple cancers, possibly
also due to the increased risk associated with anti-cancer
treatments (i.e., chemotherapy and radiotherapy). This
report confirms the cancer propensity of FA patients and
further stresses the need for frequent and careful tumor
evaluations, aiming at early therapeutic interventions,24,28
the only effective strategy for improving long-term sur-
vival in FA patients.
Our Registry was not designed to formally investigate
the impact of specific therapeutic interventions on the nat-
ural history of the disease. However, even if a head-to-
head comparison is impossible, we have separately looked
for overall survival in FA patients who have received an
HSCT, without showing any difference with non-trans-
planted patients. HSCT may cure the hematological dis-
ease associated with FA, but it does not reverse the pheno-
type that results from the involvement of extra-hemato-
logical tissues and organs.29-31 This is especially true for the
intrinsic risk of cancer due to the genetic instability typical
of FA, which might actually be increased by the pre-trans-
plant conditioning regimen and possible detrimental
A.M. Risitano et al.
324 haematologica | 2016; 101(3)
Table 3. Disease manifestations during the whole disease course.
Variable                                                                    180 Patients (%)
Hematological disease                                                                          
BMF
     no                                                                                                      8 (4)
      yes                                                                                                 172 (96)
Hematological malignancies
      no                                                                                                   166 (92)
      yes                                                                                                   14 (8)
      MDS                                                                                               9 (5)
      AML                                                                                              4 (2.5)
     Lymphoma                                                                                 1 (0.5)
Solid tumors
      no                                                                                                   160 (89)
      yes                                                                                                  20 (11)
Sites of solid tumors°                                                                         
      head/neck                                                                                   12 (7)
      liver                                                                                               3 (2)
      breast                                                                                           2 (1)
      thyroid                                                                                          2 (1)
      genital tract                                                                                 2 (1)
      lung                                                                                              1 (0.5)
      central nervous system                                                             1 (0.5)
      kidney                                                                                         1 (0.5)
      soft tissues                                                                                 1 (0.5)
      skin                                                                                             1 (0.5)
     gastrointestinal tract                                                               1 (0.5)
HSCT                                                                                                          
      no                                                                                                  78 (43.5)
      yes                                                                                                102 (56.5)
      Sibling                                                                                       39* (22)
      MUD                                                                                           49§ (27)
      CBU                                                                                               4 (2)
      Haploidentical                                                                          1 (0.5)
     Unknown                                                                                     9 (5)
Alive                                                                                                            
      yes                                                                                                  94 (52)
      no                                                                                                  86 (48)
°The total number of tumors exceeds the number of patients with cancer, since some
patients experienced multiple tumors: one patient had 4 tumors (genital tract, breast,
skin and head/neck), 4 patients had 2 tumors (head/neck and gastrointestinal tract,
head/neck and liver, head/neck and thyroid, central nervous system and Wilms). *2
from sibling cord blood units. §One was a second HSCT after a graft failure of a first
HSCT from a sibling donor
effects of GvHD.28,32 Notably, in our study the risk of solid
tumors remains high even after HSCT, but apparently it is
not increased over that of non-transplanted patients.
However, these data should be confirmed with a longer
follow-up, possibly within International studies designed
to specifically investigate this endpoint.  Our observation
that the survival of transplanted and non-transplanted
patients was not different is not surprising, because HSCT
in the context of FA carries specific challenges. Beyond the
fact that HSCT does not affect the extra-hematological
phenotype of FA, other reasons may play a role: i. HSCT
patients may be biased toward a more severe phenotype;
ii. initial patients may have received a HSCT with a non-
optimized conditioning regimen;33 iii. initial patients have
received HSCT quite late in their disease course; and iv.
longer follow-up is needed to let the positive impact of
HSCT emerge. Unfortunately, even if in recent decades
improvements in transplant procedures (e.g., the use of
reduced intensity conditioning regimens) have significant-
ly prolonged the overall survival rate of patients,31 HSCT
for FA remains associated with a poor prognosis, with a
high number of patients exposed to lethal complications.
Since the RIAF was not designed to study HSCT in the
context of FA, the actual impact of HSCT on the natural
history of FA needs to be investigated in more specific
studies that also deal with all the transplant-specific fac-
tors affecting the outcome of HSCT. Indeed, the question
is whether more recent HSCT, performed according to
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Figure 2. Overall survival. (A) Overall survival, HSCT not censored (filled area represents 95% confidence interval); (B) Overall survival, HSCT censored (filled area
represents 95% confidence interval); (C) Overall survival, according to age at diagnosis (patients were grouped based on the median age at diagnosis of 7,48 years);
(D) Overall survival, according to number of structural abnormalities; (E) Overall survival, according to DOB quartiles (HSCT not censored); (F) Overall survival: HSCT
vs. no HSCT.
A
C
E
B
D
F
transplant protocols which have been optimized over the
past years,34 have improved the outcome of FA, as com-
pared with natural history. One may anticipate that com-
bining earlier therapeutic intervention with improved
HSCT protocols may lead in the near future to improved
long-term outcomes for FA patients,35,36 especially if a lack
of an increased risk of malignancies is confirmed.
In conclusion, our registry confirms the adverse natural
history of FA, eventually leading to disappointing out-
comes that have not improved over time; thus, there is an
urgent need for effective treatment strategies. Our findings
highlight that large collaborative studies are essential to
investigate the impact of available therapeutic interven-
tions (such as transplantation), to optimize their use and to
define their role in the treatment algorithm of FA. It seems
obvious that it will only be through stronger collaboration
among physicians and scientists, National and
International Registries, and healthcare networks, that we
may hope to offer better long-term outcomes to  patients
affected by FA and to their families.  
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A.M. Risitano et al.
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Table 4. Multivariate analysis.
Variable HR 95% CI (lower) 95% CI (upper) P
Gender 1,067 0,643 1,772 0,802
Date of birth (quartiles) - - - 0,305
Age at diagnosis 0,873 0,821 0,928 <0,001
Congenital abnormalities (n>10,  except skin) 6,504 1,406 30,086 0,017
Skin hyper- hypopigmentation 0,665 0,394 1,125 0,128
Skeletal abnormalities 1,093 0,548 2,18 0,8
CNS and/or eyes abnormalities 0,84 0,377 1,873 0,67
Renal and urinary tract abnormalities 1,163 0,589 2,298 0,663
Genital tract abnormalities 0,778 0,365 1,659 0,516
Gastrointestinal tract abnormalities 1,523 0,677 3,426 0,31
Endocrine  abnormalities 0,619 0,246 1,563 0,311
Cardiovascular  abnormalities 0,399 0,129 1,234 0,111
BMF at diagnosis 1,846 0,757 4,504 0,178
BMF anytime 0,823 0,171 3,964 0,808
Hematological malignancies 1,7 0,813 3,558 0,159
Solid tumours 0,595 0,294 1,204 0,149
HSCT 0,724 0,403 1,301 0,28
Table 5. Causes of death.
Cause No HSCT (%) HSCT (%) Total (%)
Infections 14 (33) 11 (25.5) 25 (29)
Bleeding 8 (18.5) 0 (0) 8 (9.5)
Tumor 9 (21) 4 (9) 13 (15)
Liver failure 1 (2) 0 (0) 1 (1)
Kidney failure 2 (5) 0 (0) 2 (2.5)
Heart failure 1 (2) 0 (0) 1 (1)
GvHD 0 (0) 11 (25.5) 11(13)
Other TRM 0 (0) 13 (30) 13 (15)
Other  0 (0) 1 (2) 1 (1)
Unknown 8 (18.5) 3 (7) 11(13)
43 43 86
Trapianti Osp. Microcitemico - Arru L., Cossu F. (8); Monza -
Oncoematologia Pediatrica Policlinico "San Gerardo" - Longoni
D. (8); Napoli - Ematologia AOU "Federico II" - Rotoli B.,
Catalano L., Fiorillo A., Risitano A. (7); Pescara - UOC
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Ematologia Osp. "Cervello" - Fabbiano F., Mirto S. (5); Palermo
- Oncoematologia Pediatrica Osp.“Di Cristina” - Farruggia P.
(4); Roma - Pediatria Osp. “Sant'Eugenio” - Del Principe D. (4);
Bologna - Oncoematologia Pediatrica "Sant'Orsola" - Rosito P.,
Paolucci G. (3); Catania - Ematologia ed Oncologia Policlinico di
Catania - Schilirò G. (3); Parma - Pediatria e Oncoematologia
Pediatrica A.O. - Izzi G., Barone A. (3); Napoli - Dip. Pediatria
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Napoli - Pediatria AO “A. Cardarelli” - Saviano A. (2); Nocera
Inferiore - Pediatria AO “Umberto I” - Amendola G., Di
Concilio R. (2); Pesaro - Pediatria Osp. "San Salvatore" - Felici
L. (2); Roma - Oncoematologia pediatrica Policlinico "A.
Gemelli" - Lasorella A., Mastrangelo S. (2); Trieste - Emato-
oncologia Pediatrica Univ. - Rabusin M. (2); Ancona -
Oncoematologia Pediatrica - Pierani P., Fabrizzi B. (2); Avellino
- Ematologia AORN "San Giuseppe Moscati" - Volpe E.,
Cantore N. (2); Bari - Dip. Biomedicina Età Evolutiva UO
Pediatrica I Policlinico - Martire B. (2); Catanzaro - Ematologia
PO "Pugliese-Ciaccio" - Levato L. (1); Ferrara - Clinica
Pediatrica Univ. - Borgna Pignatti C. (1); Genova - Div.
Pediatria "Ospedali Galliera" - Melevendi C. (1); Perugia -
Pediatria AO - Mazzarino I. (1); Pisa - Oncoematologia
Pediatrica AO - Favre C., De Marco E. (1); Reggio Calabria -
Genetica Medica OORR “Bianchi-Melacrino” - Laganà C. (1);
Roma - UOC TCS Policlinico “Tor Vergata” - Cudillo L. (1);
Siena - Italy -Clinica Pediatrica Univ. - Acquaviva A. (1); Zurich
(Switzerland) - Kinderspital – Albisetti M. (1).
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